AzTrials
AzTrials

Tourette SyndromePhase 2NCT03651726

A Study to Examine the Efficacy of a Therapeutic THX-110 for Tourette Syndrome

A Phase 2 study testing THX-110 (dronabinol plus PEA) in people with Tourette Syndrome, run by Neurothera Labs Inc. at 2 sites in Germany.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This study evaluates the efficacy and safety of THX-110 in the management of tics and other symptoms (e.g. rage attacks, anxiety, depression, sleep difficulties) in patients with Tourette syndrome. In the first part of the study, half of the patients will receive THX-110, while the other half will receive a placebo. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Tourette Syndrome
What is being tested?
THX-110 (dronabinol plus PEA)
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
60 participants
Where
2 sitesGermany
Study dates
Aug 2018to Nov 2019
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Tourette syndrome according to DSM-5
  • Male and female subjects with an age between ≥18 and <65 years
  • Total tic score (TTS) of the YGTSS >18
  • CGI-S ≥4
  • Medication (and stimulation parameters for deep brain stimulation) for tics and comorbidities must be on a stable dose for at least 6 weeks before entering the study and subject must consent to maintain the stable dose during the study
  • Signed written informed consent and willingness to comply with treatment and follow-up procedures
Show all 9Show fewer
  • Subjects capable of understanding the investigational nature, potential risks and benefits of the clinical study
  • Women of child-bearing potential must have a negative pregnancy test (i.e., negative for urine human chorionic gonadotropin [hCG]) before first treatment with study medication. They must practice a highly effective, reliable and medically approved contraceptive regimen during the study (e.g., theoretical failure rate less than 1% per year a when used consistently and correctly), which include oral or parenteral or implanted hormonal contraception, vaginal ring releasing hormonal contraception (e.g., Nuvaring), intrauterine device or intrauterine system. Post-menopausal women may enter this study. Post-menopausal women are defined as those without menses in the past 12 months without an alternative medical cause, and with a serum follicle stimulating hormone (FSH) in the post-menopausal range. Women who are surgically sterile may enter this study with historical documentation of surgical procedure (bilateral tubal ligation or bilateral oophorectomy at least 6 weeks prior screening or hysterectomy or uterine agenesis) and a negative pregnancy test.
  • Male subjects must be willing to use a condom with sexual partners during this study and for a period of three months following the last administration of study medication until the follow-up visit. Male subjects must be willing to abstain from sperm donation for 3 months after the completion of this study.

Who cannot join

  • Comorbid OCD, ADHD, depression, or anxiety disorder when unstable and/or in need of an initial adjustment for a therapy
  • Presence of a comorbid psychiatric condition as developmental disability, psychotic illness or bipolar disorder
  • Ongoing behavioural treatment for tics
  • History of schizophrenia, seizure, psychotic, severe personality, or pervasive developmental disorder
  • Current clinical diagnosis of substance abuse or dependence
  • History of cannabis dependence
Show all 16Show fewer
  • Secondary and other chronic tic disorders or other significant neurological disorders
  • History of severe cardiac diseases, severe cardiovascular diseases, severe renal disorders, or severe hepatic diseases and/or positive for human immunodeficiency virus (HIV), hepatitis C, or hepatitis B
  • Concomitant medications have to be on stable dose since at least 6 weeks before entering the study and must be well tolerated at baseline without causing dizziness, confusion, sedation, or somnolence such as central nervous system depressants (e.g., barbiturates, benzodiazepines, ethanol, lithium, opioids, buspirone, scopolamine, antihistamines, tricyclic antidepressants, other anticholinergic agents, muscle relaxants)
  • Use of cannabis or CBM in the 30-day period prior to study entry and/or positive delta-9-THC urine test at baseline
  • Positive pregnancy test, i.e., positive for urine beta-hCG
  • Pregnant or breast-feeding women
  • Subjects who received any investigational medication or used any investigational device within 30 days prior to the first dose of study medication or is actively participating in any investigational drug or device study, or is scheduled to receive an investigational drug or to use an investigational device during the course of the study
  • Subjects with a known allergy, hypersensitivity, or intolerance to the active substances and/or excipients of study medication (e.g., cannabis, cannabinoids, sesame oil)
  • Any condition, which in the opinion of the investigator, would interfere with the evaluation of the study product or poses a health risk to the subject
  • Subjects who are employees of the sponsor or employees or close relatives of the investigator

Trial locations and contacts

2 sites in 1 country.

Kirsten Müller-Vahl, Prof. Dr. contact

+49 511 532 ext. 551

mueller-vahl.kirsten@mh-hannover.de

Christoph Schindler, Prof. Dr. contact

+49 511 5350 ext. 8300

schindler.christoph@mh-hannover.de

Germany2 sites
  • Medizinische Hochschule Hannover, Klinik für Psychiatrie, Sozialpsychiatrie und Psychotherapie

    Hanover, 30625

    Kirsten Müller-Vahl, Prof. Dr.

  • LMU Klinikum der Universität München, Klinik für Psychiatrie und Psychotherapie

    Munich, 80336

    Richard Musil, Dr. med.

Other trials in Germany

About this study

Official title: A Randomized Double Blind Placebo Controlled Proof of Concept Study to Evaluate Safety, Tolerability and Efficacy of Daily Oral THX-110 in Treating Adults With Tourette Syndrome ("Entourage")

This study evaluates the efficacy and safety of THX-110 in the management of tics and other symptoms (e.g. rage attacks, anxiety, depression, sleep difficulties) in patients with Tourette syndrome. In the first part of the study, half of the patients will receive THX-110, while the other half will receive a placebo. After completion of the first study part, patients will have the opportunity to continue into the second part of the study. In this part, all participants will receive THX-110.

Read the detailed description

THX-110 is an investigational drug and is being developed for the treatment of patients with Tourette syndrome and other conditions. THX-110 consists of an active substance from cannabis (dronabinol, tetrahydrocannabinol, THC) and PEA, a substance that occurs naturally in the human body, in animals and plants.

Dronabinol and similar active substances are already approved in some countries for the treatment of other conditions. In some countries, various cannabis-based medications are currently being used in the treatment of patients with Tourette syndrome, mostly without official approval.

PEA has already been used and well tolerated in numerous clinical trials. The combination of PEA and dronabinol is assumed to show better efficacy compared to treatment with dronabinol alone.

The planned study will evaluate the efficacy of THX-110 in the management of tics and other symptoms in patients with Tourette syndrome. Other objectives are to assess study drug dosage and to identify side effects that may be associated with the study drug.

In the first part of the study, half of the patients will receive THX-110, while the other half will receive a placebo. The treatment phase will last 12 weeks. After completion of the first part, patients can decide if they want to participate in the second part of the study. In this optional second part of the study, all patients will receive THX-110 for 12 weeks.

Being tested
THX-110 (dronabinol plus PEA), Placebo
Medical subject headings
Tourette Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • THX-110 (dronabinol plus PEA)Drug

    Also called Dronabinol, Tetrahydrocannabinol, THC, Palmidrol

    2.5 mg dronabinol capsules and 400 mg PEA tablets

  • PlaceboDrug

    Sesame oil pill manufactured to mimic 2.5 mg dronabinol capsules; cellulose pill manufactured to mimic 400 mg PEA tablets

Study groups in NCT03651726
Study groupRoleWhat they receive
THX-110 (dronabinol plus PEA)ExperimentalDouble-blind phase and extension open label phase: Dose range of 2.5 mg to 10 mg dronabinol (1 to 4 capsules) plus 800 mg PEA (2 tablets) taken orally once daily; starting dose is 2.5 mg dronabinol plus 800 mg PEA. Up-titration is performed within maximal 3 weeks. The titration phase is followed by a maintenance phase of 9 weeks at stable dose.
Receives: Drug: THX-110 (dronabinol plus PEA)
PlaceboPlacebo comparatorDouble-blind phase: Range of 1 to 4 dronabinol placebo capsules plus 2 PEA placebo tablets taken orally once daily; starting dose is 1 dronabinol placebo capsule plus 2 PEA placebo tablets. Up-titration is performed within maximal 3 weeks. The titration phase is followed by a maintenance phase of 9 weeks at stable dose.
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in YGTSS-TTS

    Absolute change in YGTSS-TTS as a continuous endpoint at week 12 of the double-blind phase (visit 9) compared to baseline.

    Measured: Baseline and week 12 of the double-blind phase

Secondary outcomes (16)
  1. Response to treatment according to YGTSS-TTS

    Key secondary endpoint is the response to treatment according to YGTSS-TTS, defined as a reduction in YGTSS-TTS of at least 20% (compared to baseline) at week 12 of the double-blind phase (visit 9).

    Measured: Baseline and week 12 of the double-blind phase

  2. YGTSS-TTS as a binary responder criterion and as a continuous endpoint at week 7 of the double-blind phase

    Measured: Baseline and week 7 of the double-blind phase

  3. YGTSS-GS (= YGTSS-TTS + YGTSS-impairment score)

    Measured: Baseline, week 7 and week 12 of the double-blind phase, week 19 and week 24 of the extension open label phase

  4. Modified Rush Video-Based Tic Rating Scale (MRVS)

    No. of Body Areas (score 0-4), Motor Tic Frequency (tics/min) (score 0-4) Phonic Tic Frequency (score 0-4) Severity of Motor Tics (score 0-4) Severity of Phonic Tics (score 0-4) Total score (0-20) 0=best, 20=worst

    Measured: Baseline, week 7 and week 12 of the double-blind phase, week 19 and week 24 of the extension open label phase

  5. Clinical Global Impression-Improvement Score (CGI-I)

    The CGI-S score obtained at the baseline (initiation) visit serves as a good basis for making this assessment. Only the following one query is rated on a seven-point scale: "Compared to the patient's condition at admission to the project [prior to medication initiation], this patient's condition is: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment."

    Measured: Baseline, week 7 and week 12 of the double-blind phase, week 19 and week 24 of the extension open label phase

  6. Clinical Global Impression-Severity Score (CGI-S)

    The CGI-Severity (CGI-S) asks the clinician one question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" which is rated on the following seven-point scale: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients.

    This rating is based upon observed and reported symptoms, behavior, and function in the past seven days. Clearly, symptoms and behavior can fluctuate over a week; the score should reflect the average severity level across the seven days.

    Measured: Baseline, week 7 and week 12 of the double-blind phase, week 19 and week 24 of the extension open label phase

  7. Adult Tic Questionnaire (ATQ)

    The ATQ includes a list of 14 common motor tics and 131 common vocal tics. For each type of tic, participants are asked to indicate its presence during the past week by selecting "yes" or "no." Subsequently, for each tic endorsed, participants indicate its frequency and intensity, both on a 4-point Likert-type scale. For the frequency ratings, scores range from a few times a week or less (1), to constantly, almost all the time during the day (4). For the intensity ratings, participants are asked to check (1) if the specific tic was very mild in intensity in the past week, (2) or higher if the tic was obviously noticeable to others; and 3 or higher if the tic was much more forceful and very noticeable to others during the past week. A separate score of tic severity was calculated by summing the intensity and frequency score, resulting in a score between 2 (minimal frequency and intensity) to 8 (maximum frequency and intensity) for each tic endorsed.

    Measured: Baseline, week 7 and week 12 of the double-blind phase, week 19 and week 24 of the extension open label phase

  8. Tourette Syndrome-Quality of Life Scale (GTS-QoL)

    HRQOL is often measured by four core questions that asked about general health status and number of unhealthy days in the Behavioral Risk Factor Surveillance System (BRFSS).

    HrQoL in GTS patients is evaluated using the generic EQ-5D instrument (ref: EuroQol-Group. EQ-5D. Available at:www.euroqol.org. 2006.). It includes a five dimension descriptive system and a visual analog scale (EQVAS). The five dimensions include ''Mobility,'' ''Self-Care,'' ''Usual Activities,'' ''Pain/Discomfort,'' and ''Anxiety/Depression.'' All dimensions are subdivided into three levels (no problems, some problems, and extreme problems). Calculation of EQ-5D index score was performed using a regression algorithm generated by Greiner et al (ref: Greiner W, et al. The measurement and valuation of health status using EQ-5D: a European perspective. Dordrecht: Kluwer Academic Publisher; 2003.)

    Measured: Baseline, week 7 and week 12 of the double-blind phase, week 19 and week 24 of the extension open label phase

  9. Pre-monitory Urge for Tics Scale (PUTS)

    The PUTS is a 9-item self-report questionnaire measuring premonitory sensations in individuals with tics. Each item is scored from 1 (not at all true) to 4 (very much true). The total score is computed by summing the 9 items. Thus, total scores range from 9 to 36, and higher scores represent greater premonitory urges. The PUTS has demonstrated good internal consistency, test-retest reliability, and construct validity among youths between 11 and 16 years of age.The present manuscript reports the first psychometric data on the 9-item PUTS in an older adolescent and adult sample.

    Measured: Baseline, week 7 and week 12 of the double-blind phase, week 19 and week 24 of the extension open label phase

  10. Beck Depression Inventory (BDI)

    Add up the score for each of the twenty-one questions. The highest possible total for the whole test would be sixty-three. This would mean the number three was answered on all twenty-one questions. Since the lowest possible score for each question is zero, the lowest possible score for the test would be zero.

    Total Score____________________Levels of Depression 1-10____________________These ups and downs are considered normal 11-16___________________ Mild mood disturbance 17-20___________________Borderline clinical depression 21-30___________________Moderate depression 31-40___________________Severe depression over 40__________________Extreme depression

    Measured: Baseline, week 7 and week 12 of the double-blind phase, week 19 and week 24 of the extension open label phase

  11. Yale-Brown Obsessive Compulsive Scale (Y BOCS)

    The YBOCS is a 10-item clinician-rated measure of OCD symptom severity. Raters assess obsessions and compulsions separately in five domains: time spent, interference, distress, resistance, and control. Each domain is rated on a scale from 0 to 4. Thus, total scores range from 0 to 40, with higher scores indicating greater symptom severity.

    Measured: Baseline, week 7 and week 12 of the double-blind phase, week 19 and week 24 of the extension open label phase

  12. Conners' Adult ADHD Rating Scale (CAARS)

    The self-report and observer forms contain an identical set of scales, subscales, and indexes with a total of 30 items : Total ADHD symptoms: Inattentive (9 items), Hyperactive-Impulsive (9 items) subscales and ADHD Index (12 items) with each item rated on a 4-point scale (0=never, 1= a little, 2=often, 3= frequently) derived from from Conners' ADHD Rating Scale (CARS).

    Measured: Baseline, week 7 and week 12 of the double-blind phase, week 19 and week 24 of the extension open label phase

  13. Beck Anxiety Inventory (BAI)

    The total score is calculated by finding the sum of the 21 items. Score of 0-21 = low anxiety Score of 22-35 = moderate anxiety Score of 36 and above = potentially concerning levels of anxiety

    Measured: Baseline, week 7 and week 12 of the double-blind phase, week 19 and week 24 of the extension open label phase

  14. Pittsburgh Sleep Quality Index (PSQI)

    The Pittsburgh Sleep Quality Index (PSQI) contains 19 self-rated questions and 5 questions rated by the bed partner or roommate (if one is available). Only self-rated questions are included in the scoring. The 19 self-rated items are combined to form seven "component" scores, each of which has a range of 0-3 points. In all cases, a score of "0" indicates no difficulty, while a score of "3" indicates severe difficulty. The seven component scores are then added to yield one "global" score, with a range of 0-21 points, "0" indicating no difficulty and "21 " indicating severe difficulties in all areas.

    Measured: Baseline, week 7 and week 12 of the double-blind phase, week 19 and week 24 of the extension open label phase

  15. 12-item short-form (SF-12) Health Survey

    The SF-12 is a multipurpose short form survey with 12 questions, all selected from the SF-36 Health Survey. The questions were combined, scored, and weighted to create two scales that provide glimpses into mental and physical functioning and overall health-related-quality of life.

    Physical and Mental Health Composite Scores (PCS \& MCS) are computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.

    Measured: Baseline, week 7 and week 12 of the double-blind phase, week 19 and week 24 of the extension open label phase

  16. Rage Attacks Questionnaire (RAQ)

    Measured: Baseline, week 7 and week 12 of the double-blind phase, week 19 and week 24 of the extension open label phase

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Aug 2018
  2. Study startAug 2018 (estimated)
  3. Primary completionNov 2019 (estimated)
  4. Study completionNov 2019 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Randomized, double-blind, placebo controlled, proof of concept study, followed by an open uncontrolled treatment phase
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03651726
Sponsor's protocol ID
THX-G18-001
Status last verified
Aug 2018
First submitted
9 Aug 2018
Last updated
29 Aug 2018
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing THX-110 (dronabinol plus PEA) in people with Tourette Syndrome, run by Neurothera Labs Inc. at 2 sites in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 29 Aug 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Kirsten Müller-Vahl, Prof. Dr. (+49 511 532 ext. 551, mueller-vahl.kirsten@mh-hannover.de), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in YGTSS-TTS (time frame: Baseline and week 12 of the double-blind phase). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Aug 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in